Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung

Th. Voshaar; E. M. App; D. Berdel; R. Buhl; J. Fischer; T. Gessler; P. Haidl; J. Heyder; D. Köhler; M. Kohlhäufl; C.-M. Lehr; H. Lindemann; H. Matthys; T. Meyer; H. Olschewski; K. D. Paul; K. Rabe; F. Raschke; G. Scheuch; T. Schmehl; G. Schultze-Werninghaus; D. Ukena; H. Worth

doi:10.1055/s-2001-19003

Pneumologie, Inhaltsverzeichnis

Pneumologie 2001; 55(12): 579-586
DOI: 10.1055/s-2001-19003

EMPFEHLUNGEN

Georg Thieme Verlag Stuttgart · New York

Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung

Arbeitsgruppe Aerosolmedizin der Deutschen Gesellschaft für PneumologieRecommendations for the Choice of Inhalatory Systems for Drug PrescriptionTh. Voshaar¹ , E. M. App² , D. Berdel³ , R. Buhl⁴ , J. Fischer⁵ , T. Gessler⁶ , P. Haidl⁷ , J. Heyder⁸ , D. Köhler⁷ , M. Kohlhäufl⁹ , C.-M. Lehr¹⁰ , H. Lindemann¹¹ , H. Matthys² , T. Meyer⁸ , H. Olschewski⁶ , K. D. Paul¹² , K. Rabe¹³ , F. Raschke⁵ , G. Scheuch⁸ , T. Schmehl⁶ , G. Schultze-Werninghaus¹⁴ , D. Ukena¹⁵ , H. Worth¹⁶

¹Krankenhaus Bethanien, Moers
²Medizinische Universitätsklinik, Freiburg
³Marien-Hospital, Wesel
⁴Medizinische Universitiätsklinik, Mainz
⁵Klinik Norderney, Norderney
⁶Universität Gießen, Gießen
⁷Fachkrankenhaus Kloster Grafschaft, Schmallenberg
⁸GSF, Institut für Inhalationsbiologie, Gauting
⁹Asklepios Fachklinik, München-Gauting
¹⁰Institut für Biopharmazie und Pharm. Technologie an der Universität des Saarlandes, Saarbrücken
¹¹Universitätskinderklinik, Gießen
¹²Universitätskinderklinik Dresden, Dresden
¹³Academisch Ziekenhuis Leiden, Leiden (NL)
¹⁴Universitätsklinik Bergmannsheil, Bochum
¹⁵Medizinische Universitätsklinik, Homburg
¹⁶Klinikum Fürth, Fürth

Abstract

Volltext

Referenzen

Literatur

1 Ad Hoc Committee on Health Literacy for the Council of Scientific Affairs, American Medical Association, Health Literacy . Report of the Council of Scientific Affairs. JAMA. 1999; 281 552-557
2 Aerosol Consensus Statement . Chest. 1991; 100 1106-1109
3 Alvine G F, Rodgers P, Fitzsimmons K M, Ahrens R C. Disposable jet nebulisers. How reliable are they?. Chest. 1992; 101 316-319
4 Armitage J M, Williams S J. Inhaler technique in the elderly. Age and Ageing. 1988; 17 275-278
5 Barry P, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur Respir J. 1994; 7 1707-1709
6 Barry P, O'Callaghan C. Poor output of salbutamol from a spacer device - the effect of spacer static charge and multiple actuations. Thorax. 1994; 49 402
7 van Beerendonk I, Mesters I, Mudde A N, Tan T D. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma. 1998; 35 273-279
8 Boe J, Dennis J H. European respiratory society nebulizer guidelines: technical aspects. Eur Respir Rev. 2000; 10 (Rev. 72) 1-237
9 Borgström L, Asking L, Beckman O, Bondesson E, Källén A, Olsson B. Discrepancy between in vitro and in vivo dose variability for a pressurized metered dose inhaler and a dry powder inhaler. J Aersosol Med. 1998; 11 (Suppl. 1) 59-64
10 Braunstein G L, Trinquet G, Harper A E. Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Eur Respir J. 1996; 9 893-898
11 Brenner M. Use of steroids in pediatric asthma. Pediatr Ann. 1989; 18 810 - 813, 816-818 (Review)
12 Brindley A, Sumby B S, Smith I J, Prime D. et al . Design, manufacture and dose consistancy of the serevent diskus inhaler. Pharm Tech Eur. 1995; 1 14-22
13 British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London et al . The British guidelines on asthma management: 1995 review and position statement. Thorax. 1997; 22 (Suppl. 1) S11
14 Brown P H, Ning A CWS, Greening A P, McLean A, Crompton G K. Peak inspiratory flow through Turbohaler® in acute asthma. Eur Respir J. 1995; 8 1940-1941
15 Brown P H, Blundell G, Greening A P, Crompton G K. Do large spacer devices reduce the systemic effects of high dose inhaled corticosteroids?. Thorax. 1990; 45 736-739
16 Bundesinstitut für Arzneimittel und Medizinprodukte . Bekanntmachung über die Zulassung und Registrierung sowie die Verlängerung der Zulassung von Arzneimitteln - Ausnahmen vom Verbot bestimmter die Ozonschicht abbauender Halogenkohlenwasserstoffe nach der FCKW-Halon-Verbots-Verordnung. Bundesanzeiger. 2000; 4 141
17 Byron P R. Pulmonary targeting with aerosols. Pharm Technol. 1987; 5 42-54
18 Byron P R, Peart J, Staniforth J N. Aerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalers. Pharm Res. 1997; 14 698-705
19 Byron P R, Patton J S. Drug delivery via the respiratory tract. J Aerosol Med. 1994; 7 49-75
20 Chinn S, Arossa W A, Jarvis D L, Luczynska C M, Burney P G. Variation in nebulizer aerosol output and weight output from the Mefar disometer: implications for multicentre studies. Eur Respir J. 1997; 10 452-456
21 Clark A R, Hollingworth A M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy human volunteers - implications for in vitro testing. J Aerosol Sci. 1993; 6 99-110
22 Cochrane G M, Horne R, Chanez P. Compliance in asthma. Respir Med. 1999; 93 763-769
23 Cochrane G M, Bala M V, Downs K E, Mauskopf J, Ben-Joseph R H. Inhaled corticosteroids for asthma therapy. Patients compliance, devices, and inhalation technique. Chest. 2000; 117 542-550
24 Crompton G K. Dry powder inhalers: advantages and limitations. J Aerosol Med. 1991; 3 151-156
25 Crompton G. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis. 1982; 63 (Suppl. 119) 101-104
26 Dalby R N, Tiano S L, Hickey A J. Medical devices for the delivery of therapeutic aerosols to the lung. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy New York: Marcel Dekker 1996: 441-474
27 Davadason S G, Everard M L, Linto J M, Le Souef P N. Comparison of drug delivery from conventional versus Venturi 1/2 nebulizers. Eur Respir J. 1997; 10 2479-2483
28 Dekhuijsen P NR. Inhalatiemedicatie bij volwassenen met obstructieve longaandoeningen: poeder of aërosol?. Ned Tijdschr Gneeskd. 1998; 141 1369-1374
29 Dennis J H. Drug nebulizer design and performance: Breath enhanced jet vs. constant output jet vs. ultrasonic. J Aerosol Med. 1995; 8 277-280
30 Dennis J H, Hendrick D J. Design characteristics for drug nebulizers. J Med Eng Technol. 1992; 16 63-68
31 Deutsche Atemwegsliga . Inhalationstherapie bei obstruktiven Atemwegserkrankungen. Pneumologie. 1994; 48 338-341
32 Deutsche Atemwegsliga . Positionspapier zu Treibgasen in Dosieraerosolen. Med Klinik. 1995; 90 617 (Nr. 11)
33 Dewsbury N J, Kenyon C J, Newman S P. The effect of handling techniques on electrostatic charge on spacer devices: a correlation with in vivo particle size analysis. Int J Parm. 1996; 137 216-264
34 Egermann H. Mischen von Feststoffen. In: Hagers Handbuch der pharmazeutischen Praxis, Band 2: Methoden Berlin: Springer Verlag 1991
35 Everard M L, Dolovich M. In vivo measurements of lung dose. In: Risgaard M, O'Callaghan C, Smaldone G (Hrsg). Drug delivery in the lung: clinical aspects. Lung biology in health and disease New York: Marcel Dekker 2000: (in press)
36 Farrer M, Francis A J, Pearce S J. Monitoring serum cortisol concentration after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device. Thorax. 1990; 45 740-742
37 Fergusson R J, Lenney J, McHardy G JR, Crompton G K. The use of the Autohaler® device by patients with severe airflow obstruction. Eur Resp J. 1991; 4 172-174
38 Ferin J, Mercer T T, Leach L J. The effect of aerosol charge on the deposition and clearance of TiO₂ particles in rats. Environ Res. 1983; 31 148-151
39 Ferron G A, Oberdörster G, Henneberg R. Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth. J Aerosol Med. 1989; 2 271-284
40 Friegang B. New method of beclometasone aerosol administration to children under 4 years of age. Can Med Assoc J. 1977; 117 1308-1309
41 Frieß S, Kutz G. Pulverinhalatoren: vom feindispersen System zum fertigen Arzneimittel. Dtsch Apoth Ztg. 1993; 133 1242-1245
42 Gottschalk B, Leupold W, Woller P. Fundamental investigations for the deposition of aerosols from radioactive solutions in the upper and lower airways. Z Erkr Atmungsorgane. 1979; 153 355-366
43 Hallworth G W. The formulation and evaluation of pressurized metered-dose inhalers. In: Ganderton D, Jones T (Hrsg). Drug Delivery to the Respiratory Tract Weinheim: VCH 1987: 87-118
44 Hansen N CG, Eyald T, Ibsen T B. Terbutaline inhalations by the Turbohaler® as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease. Respir Med. 1994; 88 267-271
45 Heyder J. Deponierung von Aerosolteilchen im Atemtrakt des Menschen. In: Scheuch G. Aerosole in der Inhalationstherapie München: Dustri 1997: 1-10
46 Heyder J, Gebhart J, Rudolf G, Schiller C F. et al . Deposition of particles in the human respiratory tract in size range 0,005 - 15 µm. J Aerosol Sci. 1986; 17 811-825
47 Hickey A J, Concessio N M, van Oort M M, Platz R M. Factors influencing the dispersion of dry powders as aerosols. Pharm Tech. 1994; 8 58-82
48 Hickey A J, Evans R M. Aerosol generation from propellant-driven MDIs. In: Hichey AJ (Hrsg.). Inhalation Aerosols: Physicals and Biological Basis for Therapy New York: Marcel Dekker 1996: 417-440
49 Hindle M, Byron P R. Dose emissions from marketed dry powder inhalers. Int J Pharmaceut. 1995; 116 169-177
50 Holzner P. FCKW-freie Aerosole und Dispergiersysteme. In: Müller RH, Hildebrand GE (Hrsg.). Pharmazeutische Technologie - Moderne Arzneiformen Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH 1996: 31-36
51 Holzner P. Pharmazeutische Aerosole: Methoden zur Erzeugung, Charakterisierung und Bewertung (Dissertation). Kiel: Christian-Albrechts-Universität Kiel 1995
52 Holzner P, Müller B W. An in vitro evaluation of various spacer devices for metered dose inhalers using the twin impinger. Int J Pharm. 1994; 106 69-75
53 Ip A Y, Arakawa T, Silvers H, Ransone C M, Niven R W. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulisation. J Pharm Sci. 1995; 84 1210-1214
54 Janssens H M, Devadason S G, Hop W CJ. et al . Varibility of aerosol delivery via spacer devices in young children in daily life. Eur Respir J. 1999; 13 787-791
55 June D. Achieving the change: challenges and successes in the formulation of CFC-free MDI's. Eur Respir Rev. 1997; 7 32-34
56 Kim C S, Trujillo D, Sackner M A. Size aspects of metered-dose inhaler aerosols. Am Rev Respir Dis. 1985; 132 137-142
57 Knoch M, Sommer E. Jet nebulizer design and function. Eur Respir Rev. 2000; 10 (Rev. 72) 183-186
58 Knoch M, Wunderlich E, Geldner S. A nebulizer system for highly reproducible aerosol delivery. J Aerosol Med. 1994; 7 229-237
59 Köhler D. Aerosols for systemic treatment. Lung. 1990; 168 (Suppl.) 677-684 (Review)
60 Köhler D. Systemic therapy with aerosols. In: Moran F, Dolovich MB, Newhouse MT, Newman SP (Hrsg.). Aerosols in Medicine Amsterdam: Elsevier Sci 1993: 303-319
61 Köhler D. Wirksamkeit und Akzeptanz von Pulverinhalatoren. Dtsch Med Wochenschr. 1995; 120 1401-1404
62 Köhler D, Grossmann J, Schümichen C, Vastag E, Matthys H. Comparing efficacy of various adrenergic MDIs with the recommended expander systems. Bull Europ Physiopath Resp. 1986; 22 662s
63 Köhler D, Simonides R, Rothfuss J, Vastag E, Daikeler G, Matthys H. Aerosolverteilungsmuster von 16 handelsüblichen Aerosolgeräten. Prax Klin Pneumol. 1983; 37 (Suppl. 1) 922-924
64 Köhler D, Fleischer W, Matthys H. Depositionsmuster von Dosieraerosolen im menschlichen Organismus. Atemw Lungenkrkh. 1985; 11 340-341
65 Köhler D, Fleischer W. Theorie und Praxis der Inhalationstherapie. München: Arcis 2000
66 Leach C L. Approaches and challenges to use freon propellant replacements. Aerosol Sci Technol. 1995; 22 329-334
67 Leach C L. Enhanced drug delivery through reformulating MDIs with HFA propellant-drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ (Hrsg.). Respiratory Drug Delivery V Buffalo Grove: Interpharm Press 1996: 133-144
68 Marshik P L. et al . A novel breath actuated device (Autohaler®) consistently actuates during the early phase of inspiration. J Aerosol Med. 1995; 8 187-195
69 Martonen T B, Katz I. Deposition mechanics of pharmaceutical particles in human airways. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy New York: Marcel Dekker 1996: 3-28
70 Martonen T B, Katz I. Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters. Pharm Res. 1993; 10 871-878
71 Melandri C, Prodi V, Tarroni G, Formignani M, De Zaiacomo T, Bompane G F, Maestri G. On the deposition of unipolarly charged particles in the human respiratory tract. Inhaled Part Pt. 1975; 1 193-201
72 Merkus P J, van Essen-Zandfliet E E, Parlevliet E, Borsboom G, Sterk P J, Kerrebijn K F, Quanjer P H. Changes of nebulizer output over the years. Eur Respir J. 1992; 5 448-491
73 Morrow-Brown H, Storey G, George W HS. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. BMJ. 1972; 2 585-590
74 Nana A, Youngchaiyud P, Maranetra N, Boe J, Löfdahl C.-G, Selroos O, Ståhl E. β₂-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med. 1998; 92 167-172
75 Newhouse M T. Aerosolerzeugung und Verteilungssysteme zur pulmonalen Medikamentenapplikation: Theorie und Praxis. Innere Medizin. 1993; 48 363-368
76 Newman S A, Morén F, Pavia D, Little F. et al . Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981; 124 17-20
77 Newman S P, Hollingworth A, Clark A R. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm. 1994; 102 127-132
78 Newman S P, Millar A B, Lennard-Jones T R, Morén F. et al . Improvement of pressurized aerosol deposition with the nebuhaler spacer device. Thorax. 1984; 39 935-941
79 Newman S P, Weisz A WB, Talaee N, Clarke S W. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. Thorax. 1991; 46 712-716
80 Newman S P, Morén F, Trofast E, Talaee N. et al . Terbutaline sulphate turbohaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm. 1991; 74 209-213
81 Newman S P, Morén F, Trofast E, Talaee N, Clarke S W. Deposition and clinical efficacy of terbutaline sulphate from Turbohaler, a new multi-dose powder inhaler. Eur Respir J. 1989; 2 247-252
82 Newman S P, Newhouse M T. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med. 1996; 9 55-70
83 Nides M A, Tashkin D P, Simmons M S. et al . Improving inhaler adherence in a clinical trial through the use of a nebulizer chronolog. Chest. 1993; 104 1332-1337
84 Nikander K. Drug delivery systems. J Aerosol Med. 1994; 7 S19-24
85 Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebuliser proved inefficient in nebulising a suspension. J Aerosol Med. 1999; 12 (Suppl. 2) 47-53
86 Niven R W, Ip A Y, Mittelman S, Prestrelski S J, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm Res. 1995; 12 53-59
87 O'Callaghan C, Cant M, Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation?. Thorax. 1994; 49 961-964
88 O'Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuation of drug. Thorax. 1993; 48 603-606
89 O'Driscoll R. Review of methodology and development of UK nebulizer guidelines (1997) prepared by the British Thoracic Society. Eur Respir Rev. 2000; 10 (Rev. 72) 203-205
90 Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med. 1994; 7 (Suppl. 1) 43-47
91 van der Palen J. Multiple inhalers confuse asthma patients. Eur Respir J. 1999; 14 1034-1037
92 Partridge M R, Woodcock A, Sheffler A L. et al . Chlorofluorocarbon-free inhalers: are we ready for the change?. Eur Respir J. 1998; 11 1006-1008
93 Patton J S, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 1999; 35 235-247
94 Pedersen S. How to use a rotahaler. Arch Dis Child. 1986; 61 11-14
95 Petro W, Gebert P, Lauber B. Ursachen fehlerhafter Anwendung von Dosieraerosolen. Pneumologie. 1994; 48 191-196
96 Pierart F, Wildhaber J H, Vrancken I, Devadason S G, Le Souef P N. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J. 1999; 13 673-678
97 Ross D L, Schultz R K. Effect on inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aerosol Med. 1996; 9 215-226
98 Sackner M A, Chong C S. Auxiliary MDI aerosol delivery systems. Chest. 1985; 88 161-169
99 Sakula A. A history of asthma. J R Coll Physicians Lond. 1988; 22 36-44
100 Saunders K B. Misuse of inhaled bronchodilator agents. BMJ. 1965; 1 1037-1038
101 Self T H, Rumbak M J, Kelso T M. Correct use of metered-dose inhalers and spacer devices. Postgrad Med. 1992; 92 95-106
102 Shim C. Spacer disuse. Am J Respir Crit Care Med. 2000; 161 A320
103 Smith E C, Denyer J, Kendrick A H. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J. 1995; 8 1214-1221
104 Smith K J, Chan H.-K, Brown K F. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med. 1998; 11 231-245
105 Stahlhofen W, Gebhardt J, Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J. 1980; 41 385-397
106 Svartengren K, Lindestad P.-A, Svartengren M, Philipson K, Bylin G, Cammer P. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med. 1995; 152 32-37
107 Tang I N, Munkelwitz H R, Davis J G. Aerosol growth studies. III. J Aerosol Sci. 1977; 8 321-330
108 The COPD guidelines group of the standards of care committee of the BTS . BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax. 1997; 52 (Suppl. 5) 1-28
109 Thompson J, Irvine T H, Grathwohl K, Roth B. Misuse of metered-dose inhalers in hospitalized patients. Chest. 1994; 105 715-717
110 Thorsson L, Edsbacker S. Lung deposition from a pressurised metered dose inhaler attached to a spacer. Eur Respir J. 1998; 12 1340-1345
111 Tiano S L, Dalby R N. Comparison of a respiratory suspension aerosolized by an airjet and an ultrasonic nebuliser. Pharm Dev Technol. 1996; 1 261-268
112 Vidgen M T, Patronen T P, Kärkkäinen A, Karjalainen P. Effect of extension devices on the drug deposition from inhalation aerosols. Int J Parm. 1987; 39 107-112
113 Visser J. Van der Waals and other cohesive forces affecting powder fluidization. Powder Technol. 1989; 58 1-10
114 Webb J, Rees J, Clark T J. A comparison of the effects of different methods of administration of beta 2 sympathomimetics in patients with asthma. Br J Dis Chest. 1982; 76 351-357
115 Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebuliser type and antibiotic concentration on device performances. Pediatr Pulmonol. 1997; 23 249-260
116 Wettengel R, Berdel D, Hoffmann D, Krause J, Kroegel C, Kroidl R F, Leupold W, Lindemann H, Magnussen H, Meister R, Moor H, Nolte D, Rabe K F, Reinhardt D, Sauer R, Schultze-Werninghaus G, Ukena D, Worth H. Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie. Med Klin. 1998; 93 639-650
117 Wetterlin K. Turbohaler: a new powder inhaler for administration of drugs to the airways. Pharm Res. 1988; 5 506-508
118 Wigley F W, Londono J H, Wood S H, Shipp J C, Waldman R H. Insulin across respiratory mucosae by aerosol delivery. Diabetes. 1971; 20 552-556
119 Wildhaber J H, Devadason S G, Hayden M J, James R, Dufty A P, Fox R A, Summers Q A, Le Souef P N. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur Respir J. 1996; 9 1943-1946
120 Winsel K, Bergmann K C, Lachmann B. Untersuchungen über die Ultraschallverneblung von oberflächenaktiven Stoffen aus Lungengewebe und Lecithin-Dispersionen im Hinblick auf die künstliche Befilmung von Lungen. Z Erkr Atmungsorgane. 1974; 140 151-158
121 Zanen P, van Spiegel P I, van der Kolk H, Tushuisen E. et al . The effect of the inhalation flow on the performance of a dry powder inhalation system. Int J Pharm. 1992; 81 199-203

Dr. Th. Voshaar

Krankenhaus Bethanien

Bethanienstr. 21

47441 Moers